Hamlet BioPharma Conducts Pre-Initiation Visit for Phase III Trial of Alpha1H in Bladder Cancer

Hamlet BioPharma AB has completed a pre-initiation visit at the Department of Urology at Charles University in Prague. This visit is a key step in the preparation for the company's Phase III clinical trial of its drug candidate Alpha1H, which is being developed for the treatment of bladder cancer.

The trial is expected to assess the efficacy and safety of Alpha1H in patients diagnosed with bladder cancer. This Phase III study represents a significant hurdle in the drug development process towards potential regulatory approval and broader patient access.

In related news, Hamlet BioPharma recently secured new patents and allowances in Japan and India concerning its cancer and infection therapies. The company also announced continued success for its new anti-infective therapies, with a paper published in The Journal of Infectious Diseases detailing non-antibiotic treatments.